Clinical trial
Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in…
NCT00116597 · University Hospital, Basel, Switzerland, Other · Completed
Key facts
| NCT number | NCT00116597 |
|---|---|
| Title | Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma |
| Official title | Active Specific Intranodal Immunotherapy With a Recombinant Vaccinia Virus Expressing Three Melanoma Associated Epitopes and Two Costimulatory Molecules, Followed by Immunization With Synthetic Melanoma Associated Epitopes. A Phase I/II Trial in Patients With Stages IIb to IV Melanoma |
| Lead sponsor | University Hospital, Basel, Switzerland, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological, Genetic |
| Interventions | Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes, Intranodal booster immunizations with synthetic melanoma associated epitopes |
| Enrollment | 15 |
| Start date | Nov 1, 2002 |
| Primary completion | Jul 1, 2007 |
| Completion | Dec 1, 2008 |
| First posted | Jun 30, 2005 |
| Last update posted | Dec 2, 2009 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: